Based on our new results, we suggest that in vitro treatment with IL-12 and IL-18, in combination, compared to IL-12 and IL-18 treatment, alone, have a prominent effect on NK cell cytotoxicity, IFN-γ production and the expression of CD25 receptor on NK cells in MM patients and especially in HC. This evidence concerns the gene IL18 and Miyoshi myopathy.